Injection of CD137 agonist mAbs expanded CD8+ effector T memory cells and promoted tumor regression in a variety of mouse tumor models in a CD8+ T cell-dependent manner (39, 40), suggesting CD137 is a promising target to increase T cell function. Here, TNFRSF9 is linked to neoplasm.